Clinical-stage pharmaceutical company Incannex Healthcare (ASX: IHL) has completed a pre-investigational new drug (IND) application meeting with the US Food and Drug Administration over IHL-216A, its proprietary drug for the treatment of traumatic brain injury (TBI) and concussion. IHL-216A is a combination of cannabidiol and isoflurane designed to be administered via inhalation soon after head […]
The post Incannex Healthcare completes US FDA meeting for IHL-216A in the treatment of traumatic brain injury appeared first on Small Caps.
from Small Caps https://ift.tt/B0VRCv2
Post a Comment